Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 221

Sort by

Sort Order Select

Journal Articles

Familial patterns of hematologic precursors

Ola Landgren, Francesco Maura

Blood (2021) 137 (15): 1992–1993.

https://doi.org/10.1182/blood.2020010035

Published: 2021

Journal Articles

Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma

Kristen M Rosenthal, PhD, Stephen M Ansell, MD PhD, John P. Leonard, MD, Julie M Vose, MDMBA, Michael L. Wang, MD, Timothy A Quill, PhD, Kevin L Obholz, PhD, Christopher R. Flowers, MD MS

Blood (2019) 134 (Supplement_1): 410.

https://doi.org/10.1182/blood-2019-124519

Published: 2019

Journal Articles

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Charles F. Lemaistre, MD, Ju-Hsien Chao, DO, Tonya Cox, BSN, RN, Jose Carlos Cruz, MD, William B. Donnellan, MD, Alireza Eghtedar, MD, Jared Holder, MA, Suman Kambhampati, MD, Shahbaz Malik, Michael B. Maris, MD, Marcello Rotta, MD, Frank Thomas Slovick, MD, Minoo Battiwalla, MD

Blood (2019) 134 (Supplement_1): 4780.

https://doi.org/10.1182/blood-2019-130640

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F. List, MD, Zhuoxin Sun, PhD, Amit Verma, MBBS, John M. Bennett, MD, Kathy McGraw, PhD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD, Timothy R. Wassenaar, MD, Selina M. Luger, MD FRCPC, Ryan J. Mattison, MD, Puneet S. Cheema, MD, Jessica K. Altman, David F. Claxton, MD, Charles A. Schiffer, MD, Andrew S. Artz, MD, Mark Litzow, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 842.

https://doi.org/10.1182/blood-2019-127274

Published: 2019

Journal Articles

Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance

Blood (2019) 134 (Supplement_1): 233.

https://doi.org/10.1182/blood-2019-124535

Published: 2019

Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor

Blood (2019) 134 (Supplement_1): 144.

https://doi.org/10.1182/blood-2019-131014

Published: 2019

Journal Articles

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)

Blood (2019) 134 (Supplement_1): 69.

https://doi.org/10.1182/blood-2019-129499

Published: 2019

Journal Articles

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Kelda Gardner, PA-C, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Anna B. Halpern, MD, Carole M. Shaw, BA, Jacob Appelbaum, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 5094.

https://doi.org/10.1182/blood-2019-131280

Published: 2019

Journal Articles

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Lina Han, PhD, Antonio Cavazos, Natalia Baran, PhDMD, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Jason P Gay, MS, Ningping Feng, PhD, Venkata Lokesh Battula, PhD, Hagop M. Kantarjian, MD, Naval G. Daver, MD, Joseph R Marszalek, PhD, Michael Andreeff, MD PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 5161.

https://doi.org/10.1182/blood-2019-124475

Published: 2019

Journal Articles

18F-Fluorodeoxyglucose Positron Emission Tomography Versus Bone Marrow Biopsy for the Evaluation of Bone Marrow Infiltration in Newly Diagnosed Lymphoma Patients: Real-World Clinical Management of Patients at the National Cancer Institute, México

Tania Aguado, MD, Antonio Olivas-Martinez, MD, Uvi Cancino-Ramos, MD, Diego Zúñiga, MD, Carmen Lome, MD, Silvia Rivas-Vera, MD, Myrna Candelaria, MD PharmD

Blood (2019) 134 (Supplement_1): 5813.

https://doi.org/10.1182/blood-2019-126231

Published: 2019

Journal Articles

Key Barriers to Clinical Trial Enrolment: A Survey of Clinical Trial Staff at an NCI Designated Cancer Center

Amany R. Keruakous, MD, Adam S. Asch, MD

Blood (2019) 134 (Supplement_1): 5864.

https://doi.org/10.1182/blood-2019-126257

Published: 2019

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Jennifer Woyach, MD, Deborah M. Stephens, DO, Ian W. Flinn, MD PhD, Seema A. Bhat, MD, Ronald E. Savage, Feng Chai, MD, Sudharshan Eathiraj, PhD, Lindsey Granlund, Lyndsey A. Szuszkiewicz, Brian Schwartz, MD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4298.

https://doi.org/10.1182/blood-2019-127260

Published: 2019

Journal Articles

Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932

Anne Angiolillo, MD, Reuven J. Schore, MD, John Kairalla, Meenakshi Devidas, Karen R. Rabin, MD PhD, Patrick A. Zweidler-McKay, MD PhD, Michael J. Borowitz, MD PhD, Brent L Wood, MD PhD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Mary V. Relling, PharmD, Ashley Lane, Kelly Maloney, MD, Cindy Wang, MS, William L. Carroll, MD, Naomi Winick, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD

Blood (2019) 134 (Supplement_1): 824.

https://doi.org/10.1182/blood-2019-123565

Published: 2019

Journal Articles

Developing the Next Generation of iPSC Cell-Based Immunotherapies

Raul Vizcardo, PhD, Nicholas Donald Klemen, MD, Rafiqul Islam, PhD, Devikala Gurusamy, PhD, Naritaka Tamaoki, MD, PhD, Li Jia, PhD, Zhiya Yu, PhD, Amanda N Hennings, PhD, Takuya Maeda, MD, Marta Bosch-Marce, PhD, Meghan L Good, MD, Svetlana Pack, PhD, David F. Stroncek, Francis A Flomerfelt, PhD, Michael J Kruhlak, PhD, Nicholas Phillip Restifo, MD

Blood (2018) 132 (Supplement 1): 3707.

https://doi.org/10.1182/blood-2018-99-118593

Published: 2018

Journal Articles

Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)

Julie A. Wolfson, MD MS, Smita Bhatia, MD MPH, Jill Ginsberg, MD, Laura Becker, MS, David Bernstein, Henry (Joe) Henk, PhD, Gary H. Lyman, MD MPH, FRCP, Paul Nathan, MD, Diane Puccetti, MD, Jennifer J. Wilkes, MD, Lena E. Winestone, MD, Kelly Kenzik, PhD

Blood (2018) 132 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2018-99-110649

Published: 2018

Journal Articles

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Marianne T. Santaguida, BSc, PhD, Christos Gekas, PhD, Todd A Alonzo, PhD, Robert B Gerbing, MA, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Tiffany Hylkema, BS, Lisa Eidenschink Brodersen, PhD, Michael R. Loken, PhD, Hamid Bolouri, PhD, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 881.

https://doi.org/10.1182/blood-2018-99-115544

Published: 2018

Journal Articles

Epigenetic Modifier Mutations in the LL-100 Panel

Hilmar Quentmeier, PhD, Claudia Pommerenke, PhD, Hans G. Drexler, MD PhD

Blood (2018) 132 (Supplement 1): 5271.

https://doi.org/10.1182/blood-2018-99-110060

Published: 2018

NARROW

Familial patterns of hematologic precursors

Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

18F-Fluorodeoxyglucose Positron Emission Tomography Versus Bone Marrow Biopsy for the Evaluation of Bone Marrow Infiltration in Newly Diagnosed Lymphoma Patients: Real-World Clinical Management of Patients at the National Cancer Institute, México

Key Barriers to Clinical Trial Enrolment: A Survey of Clinical Trial Staff at an NCI Designated Cancer Center

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932

Developing the Next Generation of iPSC Cell-Based Immunotherapies

Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Epigenetic Modifier Mutations in the LL-100 Panel

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only